| Filing date | Form | Description | Filing Group | View |
|---|---|---|---|---|
| PRRN14A | Non-management revised preliminary proxy soliciting materials |
Proxy Filings
|
||
| UPLOAD | UPLOAD |
Other
|
||
| 10-K/A | Amendment to a previously filed 10-K |
Annual Filings
|
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA | |
| SC 13D/A | An amendment to a SC 13D filing |
Other
|
||
| DFAN14A | Additional proxy soliciting materials filed by non-management |
Proxy Filings
|
||
| PREC14A | Preliminary proxy statement containing contested solicitations |
Proxy Filings
|
||
| SC 13D/A | An amendment to a SC 13D filing |
Other
|
||
| DFAN14A | Additional proxy soliciting materials filed by non-management |
Proxy Filings
|
||
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA | |
| 10-K | Annual report which provides a comprehensive overview of the company for the past year |
Annual Filings
|
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA |
Data provided by Kaleidoscope.
GNI Group, Ltd. (2160:Tokyo) (“GNI Japan”) holds an indirect, controlling interest in Gyre Therapeutics, Inc. From time to time, GNI Japan will disclose historical and forward looking information, which will include information about our business. We may not have previously disclosed such information. Please refer to https://www.gnipharma.com/ir/yuho/ for GNI Japan’s Investor Information and Securities Reports.
